A Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multi-Center Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects With Moderately Active Ulcerative Colitis.

Trial Profile

A Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multi-Center Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects With Moderately Active Ulcerative Colitis.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs AG 011 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors ActoGeniX
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 15 Mar 2012 Actual end date changed from Sep 2009 to Nov 2009 as reported by European Clinical Trials Database.
    • 15 Mar 2012 This trial is recruiting in Netherlands as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top